---

Highlights for February 2017

1. Astellas and Lupin’s subsidiary Kyowa enter into an Agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan

2. Aurobindo Pharma Forays into Biosimilars Development through an acquisition of Four Products from TL Biopharmaceutical AG

3. Alkem enters into an alliance with Haw Par for Tiger Balm products in India
4. Cipla and Zydus Cadila scouts for acquisitions separately to strengthen their US business
5. Integra offers $1B+ bid for J&J’s neurosurgery business
6. Sarepta sells Exondys 51 PRV to Gilead for $125M
7. Gene therapy specialist Renova Therapeutics takes licensing rights from Janssen for an injectable peptide drug to treat heart failure

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.